Announcement • May 22
Bioporto A/S Un-changes Earnings Guidance for the Full Year 2026 BioPorto A/S unchanged earnings guidance for the full year 2026. For the full year 2026, Guidance for 2026 remains unchanged as announced April 8, 2026. The Company therefore expects total revenue of DKK 38 million to DKK 48 million, total NGAL revenue of DKK 33 million to DKK 42 million. New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Danish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.77m free cash flow). Earnings have declined by 6.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (kr.510.0m market cap, or US$79.6m). Announcement • Apr 02
Bioporto A/S Advances U.S. Adult Urine Ngal Program with Fda Pre-Submission Request BioPorto A/S had formally submitted its FDA pre-submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary analysis recently completed for the U.S. adult urine NGAL Cut-off Study. On 18 March 2026, BioPorto reported that the preliminary analysis demonstrated results supporting the study’s primary endpoint, providing the foundation for the next phase of the Company’s regulatory strategy. Building on these findings, BioPorto has now submitted its FDA pre-submission package, seeking Agency feedback on the proposed clinical study design for the upcoming Validation Study, which is an essential step toward U.S. regulatory 510(k) clearance. With the pre-submission meeting package now filed, BioPorto seeks FDA feedback to align with the Agency on the Validation Study protocol. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026. New Risk • Mar 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr.77m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.77m free cash flow). Earnings have declined by 6.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (kr.433.2m market cap, or US$66.7m). Reported Earnings • Mar 27
Full year 2025 earnings released: kr.0.15 loss per share (vs kr.0.17 loss in FY 2024) Full year 2025 results: kr.0.15 loss per share. Revenue: kr.40.3m (up 11% from FY 2024). Net loss: kr.82.1m (loss widened 20% from FY 2024). Announcement • Mar 27
BioPorto A/S, Annual General Meeting, Apr 24, 2026 BioPorto A/S, Annual General Meeting, Apr 24, 2026, at 15:00 Romance Standard Time. Location: tuborg havnevej 15, st., dk-2900 hellerup, Denmark Announcement • Mar 20
BioPorto A S Successfully Completes Preliminary Analysis of U S Adult NGAL Cutoff Study BioPorto A/S announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of NGAL in assessing risk of acute kidney injury (AKI). The Company intends to submit its FDA Pre-submission package by the end of March 2026, to ensure robustness in its subsequent Validation Study. Patient enrollment was completed in October 2025, and database lock was finalized in March 2026. The preliminary analysis of the adult study has shown positive results supporting the study’s primary endpoint, consistent with the findings from the Company’s cutoff and validation study conducted in the pediatric segment, which subsequently led to FDA clearance at the end of 2023 for the pediatric indication. This is providing a strong foundation for BioPorto’s regulatory strategy going forward. The planned Pre-submission will seek FDA’s feedback on the regulatory pathway as well as the design of analytical and clinical study protocols for the Validation Study. Subsequently, the Validation Study will be initiated. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026. Announcement • Feb 06
BioPorto A/S Provides Its Earnings Guidance for Full Year 2026 BioPorto A/S provided its earnings guidance for full year 2026. For the year, the company For 2026, the total NGAL revenue is expected in range of DKK 48 Million to DKK 58 million. Announcement • Dec 13
BioPorto A/S Announces Resignation of CFO Niels Høy Nielsen BioPorto A/S announced that Niels Høy Nielsen has resigned as Chief Financial Officer of BioPorto to become CFO at another company. Niels Høy Nielsen will continue to serve in his current role at the Company through March 2026. New Risk • Nov 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (kr.520.8m market cap, or US$80.8m). Reported Earnings • Nov 21
Third quarter 2025 earnings released: kr.0.05 loss per share (vs kr.0.049 loss in 3Q 2024) Third quarter 2025 results: kr.0.05 loss per share (further deteriorated from kr.0.049 loss in 3Q 2024). Revenue: kr.10.4m (up 7.4% from 3Q 2024). Net loss: kr.23.3m (loss widened 12% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Nov 20
BioPorto A/S Confirms Earnings Guidance for Full Year 2025 BioPorto A/S confirmed its earnings guidance for full year 2025. For the year, the company total revenue expectation is to be in the range of DKK 40 million - DKK 45 million. New Risk • Aug 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr.87m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.87m free cash flow). Earnings have declined by 4.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr.592.0m market cap, or US$92.8m). Announcement • Jun 30
Bioporto A/S Announces Initiation of Commercialization of Pronephro Aki (Ngal) for Diagnostic Use in the Us BioPorto A/S announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AK ITM (NGAL) for the US market. This purchase order is to service US hospitals through BioPorto's distribution relationship with Roche Diagnostics. Currently, ProNephro AKI TM (NGAL) has FDA 510(k) marketing clearance for Roche's cobas®? c501 analyzers, that are broadly available in standard medical laboratories and hospitals. Reported Earnings • May 09
First quarter 2025 earnings released: kr.0.06 loss per share (vs kr.0.036 loss in 1Q 2024) First quarter 2025 results: kr.0.06 loss per share (further deteriorated from kr.0.036 loss in 1Q 2024). Revenue: kr.7.67m (down 19% from 1Q 2024). Net loss: kr.27.5m (loss widened 103% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. New Risk • Apr 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.1% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.79m net loss next year). Shareholders have been diluted in the past year (20% increase in shares outstanding). Announcement • Apr 15
BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million. BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 25,000,000
Price\Range: DKK 1.3402
Transaction Features: Subsequent Direct Listing Board Change • Apr 15
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Vice-Chairman of the Board Henrik Juuel is the most experienced director on the board, commencing their role in 2024. Independent Director Mats Thoren was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Apr 14
BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million. BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 25,000,000
Price\Range: DKK 1.3402
Transaction Features: Subsequent Direct Listing Announcement • Apr 12
BioPorto A/S Approves Board Appointments BioPorto A/S held its Annual General on April 11, 2025, elected Jens Due Olsen and Donna Haire as new members of the Board of Directors. After the Annual General Meeting, the Board of Directors constituted itself by electing Jens Due Olsen as Chair and Henrik Juuel as Vice Chair of the Board of Directors. Major Estimate Revision • Mar 28
Consensus EPS estimates upgraded to kr.0.18 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -kr.0.20 to -kr.0.18 per share. Revenue forecast unchanged from kr.52.3m at last update. Biotechs industry in Denmark expected to see average net income growth of 8.9% next year. Consensus price target up from kr.3.00 to kr.4.00. Share price fell 3.1% to kr.1.39 over the past week. Reported Earnings • Mar 20
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: kr.0.17 loss per share (further deteriorated from kr.0.16 loss in FY 2023). Revenue: kr.36.2m (up 17% from FY 2023). Net loss: kr.68.2m (loss widened 21% from FY 2023). Revenue missed analyst estimates by 9.3%. Earnings per share (EPS) exceeded analyst estimates by 5.6%. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Mar 20
BioPorto Provides Earnings Guidance for the Fiscal Year 2025 and Aspirations for 2026 Towards 2029 BioPorto A/S provided earnings guidance for the fiscal year 2025. For the year, the company is targeting total revenue of DKK 45 million to DKK 60 million, corresponding to a growth in the range of 24 % to 66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded.
For the 2026, the company aspired to reach total revenue of DKK 80 million to DKK 125 million (app. USD 12 million to USD 18 million). BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029. Announcement • Mar 06
BioPorto A/S, Annual General Meeting, Apr 11, 2025 BioPorto A/S, Annual General Meeting, Apr 11, 2025. Announcement • Mar 05
Bioporto A/S Announces Ninfa Saunders, Michael S. Singer and Don M. Hardison Will Not Seek Re-Election BioPorto A/S announced that Ninfa Saunders, Michael S. Singer and Don M. Hardison will not seek re-election at the General Meeting. Announcement • Feb 28
BioPorto A/S Appoints Hanne Søgaard as Head of Investor Relations, Effective 1 March 2025 BioPorto A/S announced that, effective 1 March 2025, Hanne Søgaard will join BioPorto as the Company's new Head of Investor Relations. Hanne brings extensive experience within Investor Relations and financial communication, having previously led Nykredit's Investor Relations and ESG initiatives. With a strong background in financial analysis and communication from her roles at Nykredit, Juristernes og Økonomernes Pensionskasse, Danske Markets, Skandia Pension, and Alm. Brand Forsikring, Hanne is well-suited to enhance Investor Relations efforts communicating and engaging with investors on strategy and helping drive strategic goals forward. Announcement • Jan 30
BioPorto A/S Announces Board Changes BioPorto A/S announced that Board Member Henrik Juuel will be appointed interim Chairman of the Board of Directors in BioPorto A/S as John McDonough steps down and resigns as Chair and member of the Board of Directors at the end of this month. Henrik Juuel joined the Board of Directors of BioPorto A/S in 2024 and has more than 30 years of experience from the Life Science industry. Henrik is EVP & CFO of Bavarian Nordic A/S since 2018. Until the Annual General Meeting on April 11, 2025, focus will be on assessing the necessary composition of the Board to address the needs of the Company during its initiation of commercialization and indication expansion phase. As announced on December 16, 2024, the Board is seeking a new Chair to be elected at the Company’s Annual General Meeting in April 2025, which can support the Company’s engagement with investors and stakeholders in the local market and contribute to the Company’s growth. Announcement • Jan 23
BioPorto A/S Announces the Publication of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL)Reference Intervals in Healthy Adult and Pediatric Individuals BioPorto A/S announced their publication of reference intervals using BioPorto's NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients. The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required step for laboratories to implement clinical tests. These findings address the critical gaps in kidney injury management and ultimately can help with earlier identification of AKI with the use of biomarkers. This BioPorto study is the largest comprehensive study to date of 629 patients with ages ranging from three months to older than 65 years. New Risk • Nov 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: kr.696.9m (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.81m net loss next year). Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.34m revenue, or US$4.8m). Market cap is less than US$100m (kr.696.9m market cap, or US$98.4m). Announcement • Nov 14
Bioporto A/S Maintains Revenue Guidance for the Year 2024 BioPorto A/S maintained revenue guidance for the year 2024. Based on the progress and results obtained in the first nine months of 2024 the company maintains Total Revenue target of DKK 40 million. Announcement • Oct 29
BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital BioPorto A/S announced the enrollment of the first patient in its US clinical study for ProNephro AKI (NGAL) with the goal of determining a cut-off point for risk stratification of moderate to severe of AKI in adult patients. BioPorto's ProNephro AKI (NGAL), currently cleared by the US Food and Drug Administration (FDA) for those 3 months through 21 years of age, has been widely recognized for its groundbreaking potential in refining AKI diagnosis. NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than previously possible. Early detection of AKI may enable prompt intervention to save lives. BioPorto's proprietary assay is a kidney injury marker versus the traditionally used serum creatinine (SCr) functional test. The cut-off study is the first of two studies which will form a substantial part of the submission for US clearance of ProNephro AKI (NGAL) in adult patients. The cut-off study seeks to enroll patients at up to 12 US sites in 2024 and 2025. After having established the cut-off, BioPorto expects to commence enrollment for the second study, the validation study, enabling the Company to submit its FDA application for adult usage of ProNephro AKI (NGAL) by 2026. Major Estimate Revision • Aug 25
Consensus EPS estimates fall by 80% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -kr.0.10 to -kr.0.18 per share. Revenue forecast unchanged at kr.40.0m. Biotechs industry in Denmark expected to see average net income growth of 4.5% next year. Consensus price target down from kr.5.00 to kr.3.00. Share price was steady at kr.2.21 over the past week. Reported Earnings • Aug 16
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: kr.0.04 loss per share (improved from kr.0.058 loss in 2Q 2023). Revenue: kr.9.20m (up 19% from 2Q 2023). Net loss: kr.15.8m (loss narrowed 19% from 2Q 2023). Revenue exceeded analyst estimates by 9.5%. Earnings per share (EPS) missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Aug 15
Bioporto A/S Affirms Earnings Guidance for 2024 BioPorto A/S affirmed earnings guidance for 2024. For the period, the company expects total revenue target of DKK 40 million. New Risk • Jul 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.32m revenue, or US$4.7m). New Risk • Jun 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.50m free cash flow). Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.32m revenue, or US$4.7m). Announcement • May 09
Bioporto A/S Provides Revenue Guidance for 2024 BioPorto A/S provided revenue guidance for 2024. For the period, the company expects total revenue target of DKK 40 million. Reported Earnings • May 08
First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023) First quarter 2024 results: kr.0.04 loss per share (improved from kr.0.048 loss in 1Q 2023). Revenue: kr.9.46m (up 18% from 1Q 2023). Net loss: kr.13.6m (loss narrowed 16% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Apr 10
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024 BioPorto A/S announced the appointment of Gry Louise Husby Larsen as its new Executive Vice President and Chief Legal Officer (CLO), and member of the Executive Management team as of April 15, 2024. Gry Louise Husby Larsen has been employed as General Counsel at BioPorto from 2011 leading the Company’s corporate legal activities within compliance, fundraising, IPR, contracts, HR and ESG ect. In the period from 2019 to 2024, Gry Louise Husby Larsen acted as external General Counsel for BioPorto while also serving as part time General Counsel for FluoGuide A/S, Algiecel A/S and Unibio A/S. Gry Louise Husby Larsen holds a Master of Law from University of Copenhagen and was an Attorney-at-law at Knop & Co. Law Firm until 2011. To further strengthen the leadership of BioPorto, the company expects to announce the appointment of a US CEO for BioPorto’s subsidiary BioPorto Inc. and a group CFO later this quarter. Announcement • Apr 05
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election BioPorto A/S announced that it has received notice that Tonni Bülow-Nielsen, due to personal reasons, will not be a candidate for the upcoming general meeting on 30 April 2024. New Risk • Apr 04
New major risk - Revenue and earnings growth Earnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.38m net loss next year). Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.31m revenue, or US$4.5m). Market cap is less than US$100m (kr.486.7m market cap, or US$70.7m). Reported Earnings • Apr 04
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Full year 2023 results: kr.0.16 loss per share (improved from kr.0.24 loss in FY 2022). Revenue: kr.31.0m (up 6.9% from FY 2022). Net loss: kr.56.3m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • Jan 10
BioPorto A/S Announces CEO Changes BioPorto A/S announced changes to the Executive Management. By mutual agreement, BioPorto’s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from January 9, 2024. Peter Mørch Eriksen has been appointed as interim CEO. The Board of Directors has as of January 9, 2024 appointed Board Member Peter Mørch Eriksen as interim CEO of the Company. Peter Mørch Eriksen will remain in his position as Board Member at least until the expiry of his election period at this year’s Annual General Meeting. Peter Mørch Eriksen has spent more than 25 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic. Peter has previously been the CEO of BioPorto in the period from 2013 – 2021 and has served as a Board Member in BioPorto since then. Further, Peter is the Chairman of FluoGuide A/S and MONSENSO A/S. Together with the Board of Directors and the BioPorto team, Peter will finalize work that has already been commenced on the Company’s plans for commercialization, FDA instrument- & indication expansion, financial guidance for 2024 and capital requirements which is to be published by mid-February 2024. Announcement • Dec 16
BioPorto A/S, Annual General Meeting, Apr 30, 2024 BioPorto A/S, Annual General Meeting, Apr 30, 2024. New Risk • Dec 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.69m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.42m net loss next year). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.33m revenue, or US$4.8m). Announcement • Dec 08
BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States BioPorto A/S announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be marketed as ProNephro AKITM (NGAL). ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker test cleared for pediatric use (aged 3 months through 21 years) in the US. ProNephro AKI (NGAL) is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI within 48-72 hours in the intensive care unit (ICU) setting. Unlike serum creatinine, a muscle by-product that is the current standard of care but slow to rise in AKI, NGAL is a direct real time marker of kidney cell damage and can potentially detect AKI days earlier than serum creatinine. Early detection of AKI may enable prompt intervention to save lives. Until now, the risk for developing or having persistent AKI has been difficult to assess early because current standard-of-care methods, such as sCr, rise slowly in AKI. As such, ProNephro AKI (NGAL) was developed to help save kidneys and lives through faster and more timely intervention. Announcement • Dec 05
BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member BioPorto A/S announced that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024. Major Estimate Revision • Nov 08
Consensus estimates of losses per share improve by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from kr.31.6m to kr.32.0m. EPS estimate increased from -kr.0.19 per share to -kr.0.16 per share. Biotechs industry in Denmark expected to see average net income growth of 30% next year. Consensus price target of kr.4.00 unchanged from last update. Share price rose 8.5% to kr.1.82 over the past week. New Risk • Nov 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr.69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr.69m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.65m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.33m revenue, or US$4.7m). Market cap is less than US$100m (kr.635.5m market cap, or US$90.4m). Announcement • Nov 01
Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023 BioPorto A/S provided revenue guidance for the fiscal year 2023, for the year, the company expects revenue of approximately DKK 30 million to DKK 33 million. Announcement • Sep 20
Bioporto A/S Announces Resignation of Neil Goldman as CFO BioPorto A/S announced that Neil Goldman has informed the Company that he has decided to resign to take up the CFO position at another company. The search for a successor will be initiated and Neil Goldman will assist with the transition until a date to be determined. Announcement • Aug 02
BioPorto A/S announced that it has received $0.11 million in funding On July 31, 2023, BioPorto A/S closed the transaction. The transaction included participation from 8 investor. Reported Earnings • Aug 02
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: kr.0.06 loss per share (further deteriorated from kr.0.05 loss in 2Q 2022). Revenue: kr.7.75m (down 8.9% from 2Q 2022). Net loss: kr.19.6m (loss widened 15% from 2Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Aug 01
BioPorto A/S Maintains Earnings Guidance for the Year 2023 BioPorto A/S maintained earnings guidance for the year 2023. Based on the progress and results obtained in the first six months of 2023, the company maintains its financial guidance for 2023. Revenue of approximately DKK 30 million to DKK 33 million. New Risk • Jun 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.62m free cash flow). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr.65m net loss next year). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr.31m revenue, or US$4.5m). Market cap is less than US$100m (kr.455.6m market cap, or US$66.6m). Board Change • May 19
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. 6 highly experienced directors. Member of Scientific Advisory Board Hilde Geus is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • May 11
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2023 results: kr.0.05 loss per share (improved from kr.0.06 loss in 1Q 2022). Revenue: kr.8.04m (up 24% from 1Q 2022). Net loss: kr.16.1m (loss narrowed 5.7% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • May 11
BioPorto A/S Maintains Financial Guidance for 2023 BioPorto A/S maintained financial guidance for 2023. Based on the progress and results obtained in the first three months of 2023, BioPorto maintains its financial guidance for 2023, as most recently described in its Annual Report 2022 of: Revenue of approximately DKK 30 million to DKK 33 million. Reported Earnings • Mar 31
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: kr.0.24 loss per share (further deteriorated from kr.0.21 loss in FY 2021). Revenue: kr.29.0m (up 19% from FY 2021). Net loss: kr.75.9m (loss widened 33% from FY 2021). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) missed analyst estimates by 4.3%. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Chairman of the Board Chris Lindop was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 18
Second quarter 2022 earnings: Revenues exceed analyst expectations Second quarter 2022 results: Revenue: kr.8.50m (up 29% from 2Q 2021). Net loss: kr.17.1m (loss widened 26% from 2Q 2021). Revenue exceeded analyst estimates by 34%. Over the next year, revenue is expected to shrink by 5.8% compared to a 174% growth forecast for the Biotechs industry in Denmark. 
